Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Solid Biosciences Inc (NASDAQ: SLDB) closed at $5.43 in the last session, down -0.91% from day before closing price of $5.48. In other words, the price has decreased by -$0.91 from its previous closing price. On the day, 0.76 million shares were traded. SLDB stock price reached its highest trading level at $5.721 during the session, while it also had its lowest trading level at $5.35.
Ratios:
We take a closer look at SLDB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.34 and its Current Ratio is at 9.34. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 26, 2025, initiated with a Buy rating and assigned the stock a target price of $14.
On January 08, 2025, Truist started tracking the stock assigning a Buy rating and target price of $16. On December 13, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $16.Wedbush initiated its Outperform rating on December 13, 2024, with a $16 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’25 when Kahn Clare bought 1,860 shares for $5.34 per share. The transaction valued at 9,924 led to the insider holds 2,960 shares of the business.
Bain Capital Life Sciences Inv bought 1,000,000 shares of SLDB for $4,030,000 on Feb 19 ’25. The 10% Owner now owns 5,034,582 shares after completing the transaction at $4.03 per share. On Feb 19 ’25, another insider, PERCEPTIVE ADVISORS LLC, who serves as the Director of the company, bought 5,000,000 shares for $4.03 each. As a result, the insider paid 20,150,000 and bolstered with 11,833,539 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLDB now has a Market Capitalization of 422829216 and an Enterprise Value of 177770048.
Stock Price History:
The Beta on a monthly basis for SLDB is 2.55, which has changed by -0.3611765 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, SLDB has reached a high of $9.04, while it has fallen to a 52-week low of $2.41. The 50-Day Moving Average of the stock is -7.01%, while the 200-Day Moving Average is calculated to be 19.78%.
Shares Statistics:
According to the various share statistics, SLDB traded on average about 1.46M shares per day over the past 3-months and 675550 shares per day over the past 10 days. A total of 77.60M shares are outstanding, with a floating share count of 58.33M. Insiders hold about 25.09% of the company’s shares, while institutions hold 83.79% stake in the company. Shares short for SLDB as of 1755216000 were 9780877 with a Short Ratio of 6.72, compared to 1752537600 on 10231952. Therefore, it implies a Short% of Shares Outstanding of 9780877 and a Short% of Float of 14.930001.
Earnings Estimates
A detailed examination of Solid Biosciences Inc (SLDB) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.4 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.75 and -$2.8 for the fiscal current year, implying an average EPS of -$2.03. EPS for the following year is -$1.98, with 10.0 analysts recommending between -$1.34 and -$2.68.
